My Treatment Approach: Hormone Receptor-Positive Breast Cancer

Expert oncologists discuss the hormone receptor–positive (HR+) breast cancer treatment landscape and their suggested approaches to treating patients in both the early and metastatic disease settings.

EP. 1: HR+ Breast Cancer: Incidence, Prognosis, and Risk Stratification

January 16th 2023

Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.

EP. 2: Patient Profile 1: A 56-Year-Old Woman with Early HR+ Breast Cancer

January 16th 2023

Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.

EP. 3: Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer

January 23rd 2023

Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.

EP. 4: Clinical Insights on the Use of Adjuvant Therapy Plus Abemaciclib in HR+ Breast Cancer

January 23rd 2023

Detailed clinical insights on the use of adjuvant therapy plus abemaciclib in patients with high-risk, early stage HR+ breast cancer.

EP. 5: Patient Profile 2: A 62-Year-Old Woman with Metastatic HR+ Breast Cancer

January 30th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, analyze a patient case of a 62-year-old woman with metastatic HR+ breast cancer.

EP. 6: Overview of Treatment Options for Patients with Breast Cancer

January 30th 2023

Breast cancer experts provide a comprehensive overview of treatment options and clinical trials in breast cancer.

EP. 7: The Role of Surgery in Breast Cancer

February 6th 2023

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

EP. 8: Treatment after Progression on CDK4/6 Inhibitors

February 6th 2023

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

EP. 9: Closing Remarks on Treating Patients with HR+ Breast Cancer

February 13th 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.